Travere Therapeutics’ (TVTX) “Overweight” Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research note released on Wednesday,Benzinga reports. Other equities analysts have also issued reports about the stock. Guggenheim reiterated a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research note on Monday, […]
Cantor Fitzgerald restated their overweight rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research note released on Wednesday,Benzinga reports. Other equities analysts have also issued reports about the stock. Guggenheim reiterated a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a research note on Monday, […]
